ASSOCIATION OF BETA BLOCKER USE AND COPD MORTALITY: A SYSTEMATIC REVIEW

Authors

  • Dwi Wahyu Setyo Irawan General Practitioner, Kediri Regency Regional General Hospital, Indonesia Author
  • Hermawan Chrisdiono Pulmonology Consultant, Kediri Regency Regional General Hospital, Indonesia Author

DOI:

https://doi.org/10.61841/vfr8c875

Keywords:

Beta blockers, COPD, Mortality

Abstract

Background: Chronic obstructive pulmonary disease (COPD) it is currently the third greatest cause of mortality worldwide and one of the main causes of morbidity

Aims: This systematic review is to review the association of beta blocker use and COPD mortality.

Methods: This study demonstrated compliance with all requirements by means of a comparison with the standards established by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020. Thus, the specialists were able to guarantee that the research was as current as feasible. Publications released between 2014 and 2024 were considered for this search strategy. This was accomplished by utilizing a number of distinct online reference sites, including Pubmed, ScienceDirect, and SagePub. It was determined that reviews, previously published works, and partially completed works would not be included.

Result: In the PubMed database, the results of our search brought up 249 articles, whereas the results of our search on SCIENCE DIRECT brought up 18.876 articles, our search on SAGEPUB brought up 4.844 articles. The results of the search conducted for the last year of 2014 yielded a total 131 articles for PubMed, 6.875 articles for SCIENCE DIRECT and 1.840 articles for SAGEPUB. In the end, we compiled a total of 8 papers, 5 of which came from PubMed, 2 of which came from SCIENCE DIRECT and 1 of which came from SAGEPUB. We included eight research that met the criteria.

Conclusion: In summary, beta blockers showed the effect to reduce the exacerbation or exacerbation related mortality of COPD in some cases. More studies needed in the future for more evidence of the use of beta blockers as the treatments in patients with COPD.

References

Whelton PK, Carey RM, Aronow WS, Casey Jr DE, Collins KJ, Himmelfarb CD. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

Chen W, thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.

Canepa M, Temporelli PL, Rossi A, Gonzini L, Nicolosi GL, Staszewsky L, et al. Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology. 2017;136(2):128–37.

Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, et al. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JACC Heart Fail. 2019;7(10):823–33.

Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271–6.

Jenkins C. Too little, too late? The underuse of beta-blockers in COPD needs evidence to address clinical uncertainty. Respirology. 2020;25(2):122–3.

Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795–803.

Smith MC, wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;871–88.

Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons. Eur Respir Rev. 2018;

Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;

Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;

Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Ann Am Thorac Soc. 2018;15(5):608–14.

Wang WW, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart Vessels. 2019;34(7):1158–67.

Cotton S, Devereux G, Abbas H, Briggs A, Campbell K, Chaudhuri R, et al. Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials. 2022;23(1):307.

Parekh TM, Helgeson ES, Connett J, Voelker H, Ling SX, Lazarus SC, et al. Lung Function and the Risk of Exacerbation in the β-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Trial. Ann Am Thorac Soc. 2022;19(10):1642–9.

Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, et al. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respir Res. 2021;22(1):272.

Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS One. 2019;14(3).

Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grönke L, et al. β-Blockers in COPD: A Cohort Study From the TONADO Research Program. Chest. 2018 Jun 1;153(6):1315–25.

Puente-Maestu L, Calle M, Ortega-González Á, Fuster A, González C, Márquez-Martín E, et al.

Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014;108(5):737–44.

Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: Time for reappraisal. Vol. 48, European Respiratory Journal. European Respiratory Society; 2016. p. 880–8.

Lopez-Campos JL, Ruiz-Ramoz M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lancet Respir Med. 2014;2(1):54–62.

Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.

Celli BR, Decramer M, Wedzicha JA, Agusti A, Criner GJ, MacNee W, et al. An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):4–27.

Downloads

Published

2024-05-13

How to Cite

Irawan, D. W. S., & Chrisdiono, H. (2024). ASSOCIATION OF BETA BLOCKER USE AND COPD MORTALITY: A SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 10(5), 85-94. https://doi.org/10.61841/vfr8c875

Similar Articles

51-60 of 73

You may also start an advanced similarity search for this article.